Deals in Depth: February 2011
Executive Summary
Astellas added Phase III tivozanib to its pipeline in a $700mm deal with Aveo. Diagnostics and analytical testing companies fared well in M&A, including Danaher's $6.8 billion acquisition of Beckman Coulter. Biopharma financing jumped 7% to $1.9 billion, and device companies also raised more money than last month - $367 million vs. $189 million.